The dangers of starting and stopping glaucoma treatmentThe notion of patients not coming in as advised for eye examinations can be troubling. For example, when a patient has an eye disease as potentially significant as glaucoma and chooses to ignore its presence, there is cause for concern on the part of the doctor.
Leveraging the evidence for patient care todayTimes are changing, and the amount of information coming at us from all directions can easily be overwhelming. This information—whether true or false—is unrelenting and has increased in magnitude over the past five years. Part of it may be the natural progression of one’s career and the expansion of one’s network, but most of it is just the sheer volume that is at our fingertips.
Study explores influence of ocular blood flow in course of glaucomaOcular blood flow has been associated with the incidence, prevalence and progression of glaucoma, but its potential causative role remains a subject for debate. Better insights may be on the horizon using OCT angiography and sophisticated mathematical modeling techniques.
Aqueous angiography: Moving toward individualized IOP control
Aqueous angiography: Moving toward individualized IOP controlAqueous angiography facilitates increased understanding of aqueous humor outflow that can provide individualized treatment for IOP control.
IOP fluctuations important factor in setting patients’ target pressureWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important.
Exploring safety, efficacy of high-intensity focused ultrasound in glaucomaHigh-intensity focused ultrasound cyclocoagulation is safe and effective in most refractory glaucomatous eyes. Complete success was achieved in 80% (24/30) of treated eyes that had undergone the maximum of three procedures.
Studying aqueous humour outflow with aqueous angiographyA pioneering dye-based technique that enables aqueous humour outflow to be studied has the potential to improve glaucoma angle-based procedures and surgery outcomes.
Novel glaucoma drug lowers IOP by unique combination of mechanismsIn a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.
Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
New concepts in diagnosis and treatmentIn the past decade, several significant advancements have been made in the arena of glaucoma diagnosis. Spectral domain optical coherence tomography (SD-OCT), newer algorithms in trend analysis of visual field studies, and combined visually evoked potential (VEP) and pattern electroretinography (ERG) studies have been the hallmarks of such recent advancements.